RSV seasons ended earlier than usual in 2022-23 and 2023-24, and typical human hMPV circulation patterns have returned since the COVID-19 pandemic.

The drugmaker is in the latter stages of development for its RSV vaccine with phase 3 results due shortly, and has just snapped up an oral antiviral for the disease by acquiring its developer ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

THE VACCINE HAS BEEN SHOWN TO REDUCE PROGRESSION TO VERY SEVERE DISEASE IN 70% OF THE CASES. ... Respiratory syncytial virus, or RSV, is a common respiratory virus that infects the nose, ...

The United States is fighting a "quad-demic" this winter with four major viruses—COVID-19, influenza, respiratory syncytial virus (RSV) and norovirus—with infants at particular risk, Dr. Ryan ...

Respiratory Syncytial Virus is a growing health concern for Indian infants. Efforts for maternal RSV vaccine faces challenges ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

Through the project, Vu aims to understand how RSV, a common infant lung infection, influences long-term respiratory health. Vu and his team hope to discover new therapies that could stop the ...

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...

COVID-19, the flu and RSV share many symptoms and may be challenging to distinguish from one another. "Flu symptoms often include high fever, cough, sore throat, congestion, muscle aches and fatigue ...